Floatz logo

gi-6207

Breast Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
59/ 100

Competitive context

686 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
VITAMIN D
University of Illinois at Chicago
Phase 4BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

gi-6207 is also rated in:

triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
36 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →